-
01:44:36 AM
Sign in with email
Forgot your password?
Register with email
Account Verification

RLFTF - RELIEF THERAPEUTICS Holding AG

03/29/21 1:05 AM
Nasdaq, OTC : BRPA, RLFTF
clinical trialcovid-19
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
NeuroRx, Inc. today reports 60-day results of the Phase 2b /3 trial of intravenously-administered ZYESAMI™ (aviptadil acetate) for the treatment of respiratory failure in critically-ill patients with COVID-19, which is being developed in collaboration
RHEA-AI
neutral
02/23/21 1:11 PM
Nasdaq, OTC : BRPA, RLFTF
covid-19
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
NeuroRx, Inc. announced today that the Phase 2b /3 trial* of ZYESAMI™ (aviptadil, previously RLF-100™) for the treatment of Respiratory Failure in critically ill patients with Covid-19 has demonstrated multidimensional benefit around its prespecified
RHEA-AI
neutral
02/09/21 7:30 AM
Nasdaq, OTC : BRPA, RLFTF
clinical trialcovid-19
NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19
NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF; OTCQB: RLFTF) today reported preliminary results from the Phase 2b /3 trial of ZYESAMI™ (aviptadil, previously RLF-100) in patients with respiratory failure due to Critical COVID-19. The
RHEA-AI
neutral